Streamline Health Solutions, Inc.

Total revenue for Q4 fiscal 2024 was $4.7 million, down from $5.4 million in Q4 fiscal 2023. For the 12 months ended January 31, 2025, revenue was $17.9 million, down from $22.6 million in fiscal 2023. SaaS revenue was $3.1 million, or 66% of total revenue, in Q4 fiscal 2024 versus $3.4 million, or 64%, a year ago; for the full year, SaaS revenue was $11.8 million, or 66% of total revenue, versus $14.1 million, or 62% in fiscal 2023. Net loss was $2.1 million in Q4 fiscal 2024 versus $1.4 million a year ago, and full-year net loss was $10.2 million versus $18.7 million in fiscal 2023. Booked SaaS ACV was $14 million at January 31, 2025 and $14.6 million at April 30, 2025, with $13.1 million implemented. Management said it anticipates achieving an EBITDA-profitable ARR run rate during the first half of fiscal 2025 and reiterated an expectation of an EBITDA-profitable run rate exiting Q2 fiscal 2025.

Ben Stilwill framed fiscal 2024 around helping clients get paid accurately and said Streamline’s solutions were delivering an annualized financial impact of more than $210 million across the client base. His main strategic emphasis was on sharpening the core eValuator and RevID value proposition, discontinuing standalone sales of the quality module, and redirecting resources toward denials prevention. He sounded constructive about demand, saying the new functionality is launching at the right time given rising payer denials and that improved client referenceability should help bookings accelerate in fiscal 2025.

B.J. Reeves highlighted the quarter’s softer top line and wider Q4 loss, but noted the full-year net loss improved because fiscal 2023 included $10.8 million of noncash impairment charges that did not recur. He pointed to the SaaS mix shift, with SaaS revenue at 66% of total revenue in both Q4 and the full year, and said booked SaaS ACV was $14 million at year-end, rising to $14.6 million by April 30, 2025, with $13.1 million implemented. He also discussed liquidity, citing $2.2 million of cash and cash equivalents at January 31, 2025, a $1 million revolver balance, a post-quarter $1 million additional draw, and an amendment to the company’s senior term loan and revolving credit covenants.

Analyst Neil Cataldi focused on three issues: how denial-prevention will affect the current customer base and marketability of eValuator, whether the faster 42-day implementation was a one-off or a new norm, and what supports confidence in a stronger bookings pipeline after a quiet start to the year. Management said denial prevention is designed to move results into the pre-bill workflow, is already resonating with clients, and is now more measurable after testing and client feedback. On implementations, Ben Stilwill said eValuator deployments are now typically two to three months or less, while RevID implementation times are also coming down as the company applies the eValuator playbook. On bookings, he said client webinars, the Oracle conference, and peer-to-peer stories are creating more top-of-funnel activity and momentum.